• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Another ho hum ASCO for Amgen

anonymous

Guest
For as good as WE think we are the rest of the oncology community sure doesn't think so. Amgen made no waves or impact at all and was barely mentioned in news updates or more importantly by our customers. We will never be a real player in therapeutic oncology. It was embarrassing. Even our booth was a joke compared to most of the other companies. Truly sad...
 

<



For as good as WE think we are the rest of the oncology community sure doesn't think so. Amgen made no waves or impact at all and was barely mentioned in news updates or more importantly by our customers. We will never be a real player in therapeutic oncology. It was embarrassing. Even our booth was a joke compared to most of the other companies. Truly sad...

Amgen needs more than kyprolis and vectibix
 












Similar threads

Replies
1
Views
2K
Amgen
anonymous
Replies
125
Views
21K
Amgen
anonymous
Replies
257
Views
50K
Amgen
anonymous
Replies
7
Views
2K
Amgen
anonymous